Switch theme
Sign up to access all valuation multiples
Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.
1995
2.7K+
LTM Revenue $205M
LTM EBITDA $55.8M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Polymed has a last 12-month revenue (LTM) of $205M and a last 12-month EBITDA of $55.8M.
In the most recent fiscal year, Polymed achieved revenue of $195M and an EBITDA of $63.9M.
Polymed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Polymed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $205M | XXX | $195M | XXX | XXX | XXX |
| Gross Profit | $137M | XXX | $130M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $55.8M | XXX | $63.9M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $47.5M | XXX | $43.2M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $41.2M | XXX | $39.5M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $19.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 30, 2025, Polymed's stock price is INR 2150 (or $25).
Polymed has current market cap of INR 218B (or $2.5B), and EV of INR 208B (or $2.4B).
See Polymed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.5B | XXX | XXX | XXX | XXX | $0.41 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 30, 2025, Polymed has market cap of $2.5B and EV of $2.4B.
Polymed's trades at 13.0x EV/Revenue multiple, and 40.2x EV/EBITDA.
Equity research analysts estimate Polymed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Polymed has a P/E ratio of 61.7x.
See valuation multiples for Polymed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 11.8x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBITDA | 43.4x | XXX | 40.2x | XXX | XXX | XXX |
| EV/EBIT | 50.9x | XXX | 58.7x | XXX | XXX | XXX |
| EV/Gross Profit | 17.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 61.7x | XXX | 68.4x | XXX | XXX | XXX |
| EV/FCF | -149.2x | XXX | -293.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPolymed's last 12 month revenue growth is 21%
Polymed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
Polymed's rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Polymed's rule of X is 80% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Polymed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 53% | XXX | 53% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 80% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma Trading | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Polymed acquired XXX companies to date.
Last acquisition by Polymed was XXXXXXXX, XXXXX XXXXX XXXXXX . Polymed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Polymed founded? | Polymed was founded in 1995. |
| Where is Polymed headquartered? | Polymed is headquartered in India. |
| How many employees does Polymed have? | As of today, Polymed has 2.7K+ employees. |
| Is Polymed publicy listed? | Yes, Polymed is a public company listed on BOM. |
| What is the stock symbol of Polymed? | Polymed trades under 531768 ticker. |
| When did Polymed go public? | Polymed went public in 1996. |
| Who are competitors of Polymed? | Similar companies to Polymed include e.g. Ansell, Farmaceutica Remedia, Etropal, Sopharma. |
| What is the current market cap of Polymed? | Polymed's current market cap is $2.5B |
| What is the current revenue of Polymed? | Polymed's last 12 months revenue is $205M. |
| What is the current revenue growth of Polymed? | Polymed revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Polymed? | Current revenue multiple of Polymed is 11.8x. |
| Is Polymed profitable? | Yes, Polymed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Polymed? | Polymed's last 12 months EBITDA is $55.8M. |
| What is Polymed's EBITDA margin? | Polymed's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Polymed? | Current EBITDA multiple of Polymed is 43.4x. |
| What is the current FCF of Polymed? | Polymed's last 12 months FCF is -$16.2M. |
| What is Polymed's FCF margin? | Polymed's last 12 months FCF margin is -8%. |
| What is the current EV/FCF multiple of Polymed? | Current FCF multiple of Polymed is -149.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
